Speakers:

• Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian, Bugworks Research Inc.
• Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua, Amicrobe, Inc.
• Discovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford, Seres
• Therapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard, Integrated BioTherapeutics
• Regulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller, HelixBind Inc.

Moderator: Erin Duffy, CARB-X

The presentation will be followed by a Q&A session.

Register now for this live webinar.